While 2017 was a busy year for biosimilar approvals by the FDA, Rick Lozano, vice president of biosimilars and integrated business development at AmerisourceBergen, feels that the biggest developments in biosimilars were those being made outside the regulatory or clinical spheres. In an interview with The Center for Biosimilars®, Lozano said that “There are distractions and defense strategies in the market that continue to be slowing the pace” of bringing biosimilars to the market.
While 2017 was a busy year for biosimilar approvals by the FDA, Rick Lozano, vice president of biosimilars and integrated business development at AmerisourceBergen, feels that the biggest developments in biosimilars were those being made outside the regulatory or clinical spheres. In an interview with The Center for Biosimilars®, Lozano said that “There are distractions and defense strategies in the market that continue to be slowing the pace” of bringing biosimilars to the market.
Lozano reported that, in his work at AmerisourceBergen, he does not see biosimilars as fitting under a typical brand-name drug platform or under a generic drug platform; instead, he is focused on developing a unique approach to these products to help them thrive in the marketplace. Among Lozano’s initiatives is helping biosimilar developers to overcome market delays through commercialization strategies, especially with respect to aligned patient services and hub services that are either similar to or “above and beyond” what the innovator offers.
“The challenge of patient service, when we saw the first few entrances into the market, is making sure you have copay assistance in place, making sure the flow of patient services goes through the provider, and having the correct hub to support that in the background," he said.
Pure-play biosimilar developers, said Lozano, may not be deeply familiar with the patient programs that the reference product sponsor has in place, and may need help with research that will allow them to implement programs, educate patients, and provide nursing support.
Patients aren’t the only stakeholders who are seeking support. According to Lozano, providers are increasingly looking to industry to provide education about biosimilar therapies. Given how critical it is to build providers’ confidence in biosimilars, “We take it upon ourselves to work with manufactures to get the support services to educate providers so they can educate their patients,” said Lozano. Through its ION Solutions program, AmerisourceBergen conducts outreach to community oncologists not only to educate them on the safety and efficacy of biosimilars, but also to reassure them that payers have the right plans in place to support biosimilars, and that these therapies will remain in the market for the long term.
Looking ahead to 2018, Lozano hopes to see alignment across stakeholder groups—from policy makers and payers to manufacturers and wholesalers—in making the marketplace for biosimilars sustainable.
“2018 needs to be a year where stakeholders align to where there’s access to these products,” said Lozano, “and policies allow [biosimilars] to be on commercial plans—allow them to have a competitive market.”
Global Biosimilar Market Projected to Reach $1.3 Trillion by 2032
April 11th 2024The global biosimilar market is projected to surge from $25.1 billion in 2022 to approximately $1.3 trillion by 2032, with a compound annual growth rate of 17.6%, driven mainly by the increasing prevalence of cancer and the cost-effectiveness of biosimilars, as outlined in a report by Towards Healthcare.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
Study: More Biosimilar Competition Is Not Lowering Patient OOP Costs
March 29th 2024Despite more biosimilars entering the market and generating significant savings for payers and health care systems, these savings are not resulting in lower out-of-pocket (OOP) costs for patients, according to a recent study.
Biosimilar Business Roundup for October 2023—Podcast Edition
November 5th 2023On this episode, we discuss the biggest news to come out of October 2023, including 3 regulatory approvals, 2 complete response letters, and new data and industry insights that have the potential to impact the entire US biosimilar industry.
Coherus Biosciences Cites Biosimilars as Main Drivers of 2023 Revenue Growth
March 14th 2024In its earnings report for the fourth quarter and full year of 2023, Coherus Biosciences detailed its rising revenue growth, which it partly attributed to increased sales for its pegfilgrastim and ranibizumab biosimilars.